Most Read Articles
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
6 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Pearl Toh, 3 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.

Diabetic cornea donor, operative complications tied to graft failure

15 Nov 2018
The future of eyesight restoration may come from a most unlikely corneal donor – pigs.

Success of Descemet stripping automated endothelial keratoplasty (DSAEK) in the early and entire postoperative period is very probable if without operative complications and when the donor does not have diabetes, a recent study has found.

Moreover, DSAEK success in the long-term postoperative period is more likely in recipients with Fuchs dystrophy vs those with pseudophakic or aphakic corneal edema (PACE).

Of the 1,330 grafts, 1,251 (94 percent) remained clear after 3 years and were deemed successful. After adjusting for preservation time (PT), an association was found between tissue from donors with diabetes (risk ratio [RR], 2.35; 99 percent CI, 1.03–5.33) as well as operative complications (RR, 4.21; 1.42–12.47) and increased risk for primary or early failure.

Preoperative diagnosis of PACE (RR, 3.59; 1.05–12.24), compared with Fuchs dystrophy, correlated with increased risk for late failure by 3 years after surgery.

There was little variation in graft success among other factors examined, as follows: donor age (RR, 1.19 per decade; 0.91–1.56 per decade), preoperative donor endothelial cell density (RR, 1.10 per 500 cells; 0.74–1.63 per 500 cells), graft diameter (RR, 1.22 per 1 mm; 0.39–3.76 per 1 mm) and injector use for graft insertion (RR, 0.92; 0.40–2.10).

“Mechanisms whereby diabetic donors and PACE recipients reduce the rate of graft success after DSAEK warrant further study,” the investigators said.

Eyes undergoing DSAEK were randomly assigned to receive a donor cornea with PT of 0–7 days (n=675) or 8–14 days (n=655). Donor, recipient and operative parameters were prospectively recorded.

Graft failure was defined as regraft for any reason, graft that failed to clear by 8 weeks after surgery, or an initially clear graft that became and remained cloudy for 90 days. Failure in the first 8 weeks was further categorized as primary donor failure or early failure, in the absence or presence of operative complications, respectively.

The investigators estimated RRs and 99 percent CIs for graft failure by using proportional hazards and logistic regression models.

Editor's Recommendations
Most Read Articles
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
6 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Pearl Toh, 3 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.